On November 17, 2025 Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, reported an invitation to a live webcast at 10:00am CET on Monday 24 November 2025.
In the webcast, CTO Dr. Thomas B Hansen will present Circio´s latest in vitro and in vivo results on the circVec circular RNA expression platform. Recent findings include design and testing of novel circVec constructs and extended in vivo screening and validation of circVec for AAV gene therapy.
CEO Dr. Erik D Wiklund will provide a general corporate and strategy update.
Presenters:
CEO Dr. Erik Digman Wiklund
CTO Dr. Thomas Birkballe Hansen
Time: 10:00 CET on 24 November 2025
Click here to access Teams webcast
Meeting ID: 366 918 860 415 63
Passcode: Kn2Pq9pM
Questions can be submitted in advance by email to Erik D Wiklund: [email protected] or directly in the live webcast
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
(Press release, Circio, NOV 17, 2025, View Source [SID1234660016])